share_log

益丰药房(603939.SH)实控人提议公司实施2024年度中期分红 拟每10股派2.50元

The controlling shareholder of yifeng pharmacy chain (603939.SH) proposed that the company implement mid-term dividend for 2024, with a proposed dividend of 2.50 yuan per 10 shares.

Zhitong Finance ·  Jul 15 04:58

Yifeng Pharmacy Chain (603939.SH) announced that the actual controller and the chairman of the board of directors, Gao Yi, proposed: to formulate and implement the mid-term dividend plan for 2024 on the premise of complying with the profit distribution principles stipulated in the "Articles of Association" and ensuring the normal operation and long-term development of the company. It is proposed to distribute cash dividends of RMB 2.50 (tax included) per 10 shares to all shareholders based on the total share capital of the company on the record date for the implementation of equity distribution. The specific profit distribution plan will be determined by the company in combination with its own operating conditions and submitted to the board of directors, the supervisory committee and the shareholders' meeting for review and approval.

Yifeng Pharmacy Chain (603939.SH) announced that the actual controller and the chairman of the board of directors, Gao Yi, proposed: to formulate and implement the mid-term dividend plan for 2024 on the premise of complying with the profit distribution principles stipulated in the "Articles of Association" and ensuring the normal operation and long-term development of the company. It is proposed to distribute cash dividends of RMB 2.50 (tax included) per 10 shares to all shareholders based on the total share capital of the company on the record date for the implementation of equity distribution. The specific profit distribution plan will be determined by the company in combination with its own operating conditions and submitted to the board of directors, the supervisory committee and the shareholders' meeting for review and approval.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment